Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015:2015:341583.
doi: 10.1155/2015/341583. Epub 2015 Apr 30.

Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome

Affiliations
Review

Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome

Alicia A Thorp et al. J Diabetes Res. 2015.

Abstract

Sympathetic tone is well recognised as being implicit in cardiovascular control. It is less readily acknowledged that activation of the sympathetic nervous system is integral in energy homeostasis and can exert profound metabolic effects. Accumulating data from animal and human studies suggest that central sympathetic overactivity plays a pivotal role in the aetiology and complications of several metabolic conditions that can cluster to form the Metabolic Syndrome (MetS). Given the known augmented risk for type 2 diabetes, cardiovascular disease, and premature mortality associated with the MetS understanding the complex pathways underlying the metabolic derangements involved has become a priority. Many factors have been proposed to contribute to increased sympathetic nerve activity in metabolic abnormalities including obesity, impaired baroreflex sensitivity, hyperinsulinemia, and elevated adipokine levels. Furthermore there is mounting evidence to suggest that chronic sympathetic overactivity can potentiate two of the key metabolic alterations of the MetS, central obesity and insulin resistance. This review will discuss the regulatory role of the sympathetic nervous system in metabolic control and the proposed pathophysiology linking sympathetic overactivity to metabolic abnormalities. Pharmacological and device-based approaches that target central sympathetic drive will also be discussed as possible therapeutic options to improve metabolic control in at-risk patient cohorts.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Role of the central sympathetic nervous system in metabolic control.
Figure 2
Figure 2
Schematic illustration of central sympathetic nerve overactivity as a consequence and cause of metabolic abnormalities. IR: insulin resistance; SNS: sympathetic nervous system.

References

    1. Alberti K. G. M. M., Zimmet P., Shaw J. The metabolic syndrome—a new worldwide definition. The Lancet. 2005;366(9491):1059–1062. doi: 10.1016/s0140-6736(05)67402-8. - DOI - PubMed
    1. Ford E. S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28(7):1769–1778. doi: 10.2337/diacare.28.7.1769. - DOI - PubMed
    1. Malik S., Wong N. D., Franklin S. S., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110(10):1245–1250. doi: 10.1161/01.CIR.0000140677.20606.0E. - DOI - PubMed
    1. Dekker J. M., Girman C., Rhodes T., et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005;112(5):666–673. doi: 10.1161/CIRCULATIONAHA.104.516948. - DOI - PubMed
    1. Lee Z. S. K., Critchley J. A. J. H., Tomlinson B., et al. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism: Clinical and Experimental. 2001;50(2):135–143. doi: 10.1053/meta.2001.19502. - DOI - PubMed

Publication types